Mainz Biomed (MYNZ) Stock Price, News & Analysis

Company Overview

Mainz Biomed NV is a molecular diagnostics company specializing in the development and commercialization of epigenetic and genetic testing solutions for the early detection of cancer. Founded in 2004 and headquartered in Reston, Virginia, with research facilities in Mainz, Germany, the company leverages proprietary methylation marker technology to create non-invasive screening tests. Mainz Biomed’s initial focus on colorectal cancer screening led to the launch of its flagship test, ColoCaller, designed to detect methylated DNA biomarkers in stool samples to identify patients at risk for colorectal neoplasia.

Beyond its core colorectal cancer product, Mainz Biomed has expanded its pipeline to include tests for liver, gastric and pancreatic cancers. The company’s HelioLiver test targets hepatocellular carcinoma, while HelioGastric and HelioPanc are in various stages of validation for gastric and pancreatic cancer screening, respectively. Utilizing a combination of epigenetic markers and advanced bioinformatics, these assays aim to offer high sensitivity and specificity in a simple blood-draw format, addressing unmet needs in early cancer detection and intervention.

Mainz Biomed operates across Europe and the United States, collaborating with academic institutions, research hospitals and commercial partners to validate its assays and prepare for regulatory submissions. The company has established strategic partnerships to facilitate clinical trials, real-world data collection and market access in key geographies. As regulatory frameworks for liquid biopsy and molecular diagnostics evolve, Mainz Biomed continues to engage with governing bodies to secure pathway approvals and reimbursement coverage.

Under the leadership of CEO Dr. Christoph Stegelmann, Mainz Biomed combines scientific expertise with a commercialization-focused approach. The management team includes seasoned professionals in product development, regulatory affairs and business development, all working to transition novel diagnostic tools from laboratory research into routine clinical practice. With a clear strategic roadmap, Mainz Biomed is positioned to address significant gaps in cancer screening and support the global shift toward earlier, more personalized diagnostic protocols.

Key Stats

• Today's Range: $1.62 to $2.12
• 50-Day Range: $1.38 to $2.81
• 52-Week Range: $1.34 to $19.00
• Volume: 1.16 million shs
• Average Volume: 145,681 shs
• Market Capitalization: $6.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.00
• Consensus Rating: Moderate Buy

Mainz Biomed Stock Analysis - MarketRank™

Mainz Biomed scored higher than 57% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Mainz Biomed has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Mainz Biomed has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Mainz Biomed are expected to grow in the coming year, from ($23.60) to ($9.20) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Mainz Biomed is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mainz Biomed is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mainz Biomed has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.72% of the float of Mainz Biomed has been sold short.

Short Interest Ratio / Days to Cover

Mainz Biomed has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mainz Biomed has recently increased by 712.82%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mainz Biomed does not currently pay a dividend.

Dividend Growth

Mainz Biomed does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.72% of the float of Mainz Biomed has been sold short.

Short Interest Ratio / Days to Cover

Mainz Biomed has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mainz Biomed has recently increased by 712.82%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 1.87

News Sentiment

Mainz Biomed has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Mainz Biomed this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for MYNZ on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mainz Biomed insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.20% of the stock of Mainz Biomed is held by insiders. A high percentage of insider ownership can be a sign of company health.

MYNZ Stock Analysis - Frequently Asked Questions

How have MYNZ shares performed this year?

Mainz Biomed's stock was trading at $4.32 on January 1st, 2025. Since then, MYNZ stock has decreased by 54.2% and is now trading at $1.98.

How were Mainz Biomed's earnings last quarter?

Mainz Biomed NV (NASDAQ:MYNZ) issued its earnings results on Tuesday, August, 15th. The company reported ($22.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($16.80) by $5.60. The business earned $0.25 million during the quarter, compared to analyst estimates of $0.25 million.

When did Mainz Biomed's stock split?

Mainz Biomed's stock reverse split before market open on Tuesday, December 3rd 2024.The 1-40 reverse split was announced on Friday, November 29th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Mainz Biomed IPO?

Mainz Biomed (MYNZ) raised $10 million in an initial public offering (IPO) on Friday, November 5th 2021. The company issued 2,000,000 shares at a price of $4.00-$6.00 per share. Boustead Securities acted as the underwriter for the IPO.

How do I buy shares of Mainz Biomed?

Shares of MYNZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Mainz Biomed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mainz Biomed investors own include Sangamo Therapeutics (SGMO), Meta Platforms (META), NVIDIA (NVDA), Ford Motor (F), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD) and PayPal (PYPL).

Company Calendar

• Last Earnings: 8/15/2023
• Today: 7/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MYNZ
• CIK: 1874252
• Web: mainzbiomed.com
• Phone: 49-6131-554-2860
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Mainz Biomed: $14.00
• High Price Target: $14.00
• Low Price Target: $14.00
• Potential Upside/Downside: +607.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.14
• Current Ratio: 1.32
• Quick Ratio: 1.26

Sales & Book Value

• Annual Sales: $893.99 thousand
• Price / Sales: 7.62
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.61 per share
• Price / Book: 0.76

Miscellaneous

• Outstanding Shares: 3,440,000
• Free Float: N/A
• Market Cap: $6.81 million
• Optionable: Not Optionable
• Beta: 0.21